Cargando…
RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual Biosamples
Tumor mutation burden (TMB) is a well-known efficacy predictor for checkpoint inhibitor immunotherapies. Currently, TMB assessment relies on DNA sequencing data. Gene expression profiling by RNA sequencing (RNAseq) is another type of analysis that can inform clinical decision-making and including TM...
Autores principales: | Sorokin, Maxim, Gorelyshev, Alexander, Efimov, Victor, Zotova, Evgenia, Zolotovskaia, Marianna, Rabushko, Elizaveta, Kuzmin, Denis, Seryakov, Alexander, Kamashev, Dmitry, Li, Xinmin, Poddubskaya, Elena, Suntsova, Maria, Buzdin, Anton |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506044/ https://www.ncbi.nlm.nih.gov/pubmed/34650919 http://dx.doi.org/10.3389/fonc.2021.732644 |
Ejemplares similares
-
Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3′ Oncogenes from FFPE Bulk RNA Sequencing Data
por: Rabushko, Elizaveta, et al.
Publicado: (2022) -
RNA Sequencing for Personalized Treatment of Metastatic Leiomyosarcoma: Case Report
por: Seryakov, Alexander, et al.
Publicado: (2021) -
Experimental and Meta-Analytic Validation of RNA Sequencing Signatures for Predicting Status of Microsatellite Instability
por: Sorokin, Maksim, et al.
Publicado: (2021) -
Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data
por: Sorokin, Maxim, et al.
Publicado: (2022) -
Mutation Enrichment and Transcriptomic Activation Signatures of 419 Molecular Pathways in Cancer
por: Zolotovskaia, Marianna A., et al.
Publicado: (2020)